Projects per year
Personal profile
Education
- 2006-2008 M.S., Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University
- 1990-1997 M.D., School of Medicine, College of Medicine, Taipei Medical University
Experience
- Director, Department of Pathology, Taipei Medical University Shuang Ho Hospital
- 2020.05- Assistant Professor, Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University
- 2012.08-2013.07 Research Scholar/Visiting Scholar, Department of Pathology, Brown University
- 2008.02-2020.05 Instructor, Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University
- Attending Physician, Department of Pathology, Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare
- 2007.11-2011.01 Attending Physician, Department of Pathology, Taipei Medical University Hospital
- 2003.06-2007.10 Attending Physician, En Chu Kong Hospital
- 2002.12-2003.05 Attending Physician, Taipei Medical University Hospital
- 1998.03-2002.11 Resident Physician, Taipei Medical University Hospital
Fingerprint
Dive into the research topics where Phui-Ly Liew is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Finished
-
Molecular Classification of Endometrial Cancer by Bhlhe22 Subtypes in Normal Endometrium
8/1/21 → 7/31/22
Project: A - Government Institution › b - Ministry of Science and Technology
-
Association of immunohistochemical profiles with histotypes in endometrial carcinomas
Lin, C. M., Lin, S. F., Lee, Y. C., Lai, H. C. & Liew, P. L., Sept 2022, In: Taiwanese Journal of Obstetrics and Gynecology. 61, 5, p. 823-829 7 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer
Darmawi, Chen, L. Y., Su, P. H., Liew, P. L., Wang, H. C., Weng, Y. C., Huang, R. L. & Lai, H. C., Jul 1 2022, In: International journal of molecular sciences. 23, 13, 7158.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Epigenomic Analysis Reveals the KCNK9 Potassium Channel as a Potential Therapeutic Target for Adenomyosis
Chu, L. H., Liao, C. C., Liew, P. L., Chen, C. W., Su, P. H., Wen, K. C., Lai, H. C., Huang, R. L. & Chen, L. Y., Jun 1 2022, In: International journal of molecular sciences. 23, 11, 5973.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer
Lin, R. K., Su, C. M., Lin, S. Y., Thi Anh Thu, L., Liew, P. L., Chen, J. Y., Tzeng, H. E., Liu, Y. R., Chang, T. H., Lee, C. Y. & Hung, C. S., Dec 2022, In: Molecular Medicine. 28, 1, 67.Research output: Contribution to journal › Article › peer-review
Open Access4 Citations (Scopus) -
Epigenetic biomarker and drug development in gynecological cancers
Su, P. H., Chen, L. Y., Huang, R. L., Wen, K. C., Liew, P. L. & Lai, H. C., Jan 1 2021, Epigenetics in Precision Medicine. Elsevier, p. 223-255 33 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter
Datasets
-
Additional file 1 of Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Lin, Y. (Contributor), Wen, K. (Creator), Sung, P. (Contributor), Chou, Y. (Creator), Liew, P. (Contributor), Chen, L. (Contributor), Huang, R. (Creator), Lai, H. (Contributor) & Chang, L. (Contributor), Figshare, 2020
DOI: 10.6084/m9.figshare.13352142.v1, https://springernature.figshare.com/articles/figure/Additional_file_1_of_Complete_remission_of_heavily_treated_ovarian_clear_cell_carcinoma_with_ARID1A_mutations_after_pembrolizumab_and_bevacizumab_combination_therapy_a_case_report/13352142/1
Dataset
-
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Lin, Y. (Contributor), Wen, K. (Creator), Sung, P. (Contributor), Chou, Y. (Creator), Liew, P. (Contributor), Chen, L. (Contributor), Huang, R. (Creator), Lai, H. (Contributor) & Chang, L. (Contributor), Figshare, 2020
DOI: 10.6084/m9.figshare.c.5234313.v1, https://springernature.figshare.com/collections/Complete_remission_of_heavily_treated_ovarian_clear_cell_carcinoma_with_ARID1A_mutations_after_pembrolizumab_and_bevacizumab_combination_therapy_a_case_report/5234313/1
Dataset